AZTR receives NYSE delisting warning over equity requirement
McKesson Corporation’s stock reached an all-time high of 770.24 USD recently, reflecting a significant milestone for the $95.3 billion market cap company. According to InvestingPro analysis, the company maintains a "GREAT" financial health score, with analysts setting price targets ranging from $680 to $864. Over the past year, McKesson’s stock has delivered an impressive 54.77% return, supported by robust revenue growth of 20.35%. This substantial growth underscores the company’s strong market performance and investor confidence. InvestingPro data reveals 17 additional key insights about McKesson’s performance and outlook, available to subscribers. The healthcare services and information technology company has been navigating the evolving landscape effectively, which is reflected in its stock’s upward trajectory. As McKesson continues to adapt and innovate, its stock performance remains a focal point for investors and analysts alike, with current analysis suggesting the stock is trading near its Fair Value.
In other recent news, McKesson has seen several adjustments to its stock price targets following its Investor Day. TD Cowen raised its price target to $864, citing McKesson’s increased long-term earnings per share guidance and higher targets for its North America Pharmaceutical and Oncology segments. UBS also increased its price target to $860, highlighting the company’s strong cash flow and strategic reinvestment plans. Mizuho adjusted its target to $770, noting the company’s revised EPS growth guidance from 12-14% to 13-16%. Similarly, Leerink Partners raised its target to $850, attributing the change to growth in McKesson’s pharmaceutical segments. In contrast, Jefferies lowered its target to $84 due to tariff and geopolitical pressures but maintained a Buy rating. These developments reflect a mixed but generally positive outlook from analysts on McKesson’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.